Valeant acquires Nicox’s US subsidiary

Wednesday, November 19 2014 | 00 h 00 min | Acquisitions

Valeant acquires Nicox Inc., Nicox’s US subsidiary specialized in diagnostic tests.

The deal is worth up to US$20 million, with US$10 million to be paid out upfront.

Nicox will concentrate on ophthalmic therapeutics. It intends to build an international ophthalmic company in Europe and in the United States, in light of its acquisition of Aciex and positive phase 3 results for Vesneo® (latanoprostene bunod).

Expected to be launched in 2016, this glaucoma therapy is under license by the Valeant division Bausch + Lomb. Valeant estimates that the drug’s potential peak global sales will exceed CA$1 billion.

For further information: http://www.nicox.com/news-media/news/acquisition-nicoxs-us-ophthalmic-diagnostics-subsidiary-valeant-2/